<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01438125</url>
  </required_header>
  <id_info>
    <org_study_id>HAL-0082</org_study_id>
    <nct_id>NCT01438125</nct_id>
  </id_info>
  <brief_title>MF-4181 for the Reduction of Scars Secondary to Abdominoplasty or Laparoscopy/Laparotomy Gynecologic Procedures</brief_title>
  <official_title>A Pilot Study to Evaluate the Safety and Preliminary Efficacy of MF-4181 for the Reduction of Scars Secondary to Abdominoplasty or Laparoscopy/Laparotomy Gynecologic Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Halscion, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Halscion, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety and preliminary efficacy of MF-4181, a
      hydrogel scaffold, in improving scars and their resulting consequences following
      abdominoplasty or laparoscopy/laparotomy gynecologic procedures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, defined as the absence of device related serious adverse events at 3 months post last MF-4181 treatment</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator and Subject Observer Scar Assessment Scale (POSAS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator and Subject Anchored Visual Analog Scar Evaluation Scale</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital photographs evaluated by independent medical experts</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Scars</condition>
  <arm_group>
    <arm_group_label>MF-4181</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Scar halves randomized to treatment with device, opposite side treated per standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard surgical wound closure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MF-4181</intervention_name>
    <description>Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.</description>
    <arm_group_label>MF-4181</arm_group_label>
    <other_name>Hydrogel scaffold</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard surgical wound closure</intervention_name>
    <description>Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.</description>
    <arm_group_label>Standard surgical wound closure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects between 18 and 60 years of age undergoing abdominoplasty
             without intraoperative flexion at time of skin excision OR female subjects between 18
             and 60 years of age undergoing diagnostic and/or operative laparoscopy/laparotomy
             gynecologic procedures.

          -  Weight between 50 and 95 kg with BMI between 20 and 30

          -  Able and willing to give written informed consent

          -  Willing to comply with the follow-up schedule

        Exclusion Criteria:

          -  Need of concomitant surgical procedures that would be performed at the same time as
             the index surgical procedure or that would influence the healing process

          -  Previous abdominal surgery with scars or adhesions that would limit or complicate the
             index surgical procedure

          -  Presence of ventral or umbilical hernia requiring the use of prosthetic material

          -  Heart disease

          -  Pregnant or planning to become pregnant during the course of the study; the exception
             to this exclusion is if ectopic pregnancy is the reason for the procedure

          -  History of coagulopathy or bleeding disorder

          -  An American Society of Anesthesiologists (ASA) Score of &gt;II

          -  Known diabetes

          -  Current or history of heavy smoking (i.e., 10 pack years)

          -  Active skin disorder or other condition that may interfere with healing or history of
             such a condition

          -  Planned use of an ON-Q® pain control device (I-Flow Corporation, Lake Forest, CA) or
             similar incisional intervention post index procedure

          -  Active collagen vascular disease or vasculitis, e.g., systemic lupus erythematosus,
             polyarteritis, dermatomyositis, systemic scleroderma or thrombotic thrombocytopenic
             purpura

          -  Anticipated use of DERMABOND® or another topical skin adhesive type of wound closure

          -  Unwilling or unable to return for follow-up visits

          -  Regular, continuous use of systemic corticosteroid therapy or topical corticosteroid
             use in the area to be treated

          -  Current participation or participation within the last 3 months in the study of an
             investigational drug, device, or biologic

          -  Unable or unwilling to follow post-operative instructions

          -  Known hypersensitivity to MF-4181, dextran, or any of its constituent materials

          -  Previous participation in this study to avoid multiple enrollments of an individual
             subject.

          -  Chemotherapy or hormone therapy for cancer within the last 3 months, or probability
             that these treatments will be required during the 6 months of study participation.

          -  Current or past radiation therapy in the abdominal incision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wlodzimierz Baranowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unaffliated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>II Katedra i Klinika Ginekologii Onkologicznej i Ginekologii</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Ginekologii Operacyjnej</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Ginekologii i Ginekologii Onkologicznej</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>September 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <last_update_submitted>March 28, 2013</last_update_submitted>
  <last_update_submitted_qc>March 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

